Compare OVBC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | CRBP |
|---|---|---|
| Founded | 1872 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 170.3M |
| IPO Year | N/A | N/A |
| Metric | OVBC | CRBP |
|---|---|---|
| Price | $41.53 | $8.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.29 |
| AVG Volume (30 Days) | 15.9K | ★ 511.8K |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 3.01 | N/A |
| Revenue | ★ $64,211,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $13.80 | ★ N/A |
| Revenue Growth | ★ 11.98 | N/A |
| 52 Week Low | $21.86 | $4.64 |
| 52 Week High | $42.00 | $20.56 |
| Indicator | OVBC | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 73.04 | 25.11 |
| Support Level | $38.36 | $9.44 |
| Resistance Level | $42.00 | $11.64 |
| Average True Range (ATR) | 1.01 | 0.75 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 90.48 | 3.64 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services within Southeastern Ohio as well as western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers and other standard banking products and services.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.